JP2021523696A - Dnaメチル化の標的化された編集によるsnca発現の下方調節 - Google Patents

Dnaメチル化の標的化された編集によるsnca発現の下方調節 Download PDF

Info

Publication number
JP2021523696A
JP2021523696A JP2020558973A JP2020558973A JP2021523696A JP 2021523696 A JP2021523696 A JP 2021523696A JP 2020558973 A JP2020558973 A JP 2020558973A JP 2020558973 A JP2020558973 A JP 2020558973A JP 2021523696 A JP2021523696 A JP 2021523696A
Authority
JP
Japan
Prior art keywords
activity
snca
fusion protein
seq
grna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020558973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523696A5 (cg-RX-API-DMAC7.html
Inventor
オーニット チバ−ファレク
オーニット チバ−ファレク
ボリス カンター
ボリス カンター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2021523696A publication Critical patent/JP2021523696A/ja
Publication of JP2021523696A5 publication Critical patent/JP2021523696A5/ja
Priority to JP2024019364A priority Critical patent/JP2024073420A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020558973A 2018-04-23 2019-04-23 Dnaメチル化の標的化された編集によるsnca発現の下方調節 Pending JP2021523696A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024019364A JP2024073420A (ja) 2018-04-23 2024-02-13 Dnaメチル化の標的化された編集によるsnca発現の下方調節

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862661134P 2018-04-23 2018-04-23
US62/661,134 2018-04-23
US201862676149P 2018-05-24 2018-05-24
US62/676,149 2018-05-24
US201962789932P 2019-01-08 2019-01-08
US62/789,932 2019-01-08
US201962824195P 2019-03-26 2019-03-26
US62/824,195 2019-03-26
PCT/US2019/028786 WO2019209869A2 (en) 2018-04-23 2019-04-23 Downregulation of snca expression by targeted editing of dna-methylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024019364A Division JP2024073420A (ja) 2018-04-23 2024-02-13 Dnaメチル化の標的化された編集によるsnca発現の下方調節

Publications (2)

Publication Number Publication Date
JP2021523696A true JP2021523696A (ja) 2021-09-09
JP2021523696A5 JP2021523696A5 (cg-RX-API-DMAC7.html) 2022-05-06

Family

ID=68294262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558973A Pending JP2021523696A (ja) 2018-04-23 2019-04-23 Dnaメチル化の標的化された編集によるsnca発現の下方調節
JP2024019364A Pending JP2024073420A (ja) 2018-04-23 2024-02-13 Dnaメチル化の標的化された編集によるsnca発現の下方調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024019364A Pending JP2024073420A (ja) 2018-04-23 2024-02-13 Dnaメチル化の標的化された編集によるsnca発現の下方調節

Country Status (7)

Country Link
US (1) US20210189361A1 (cg-RX-API-DMAC7.html)
EP (1) EP3784785A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021523696A (cg-RX-API-DMAC7.html)
CN (1) CN112166194A (cg-RX-API-DMAC7.html)
AU (1) AU2019261361A1 (cg-RX-API-DMAC7.html)
CA (1) CA3097755A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019209869A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019255789B2 (en) 2018-04-19 2025-11-20 The Regents Of The University Of California Compositions and methods for gene editing
SG11202102012SA (en) * 2018-08-28 2021-04-29 Pharos Vaccine Inc Improved lentiviral vector
BR112021021178A2 (pt) 2019-04-26 2022-03-15 Allogene Therapeutics Inc Receptores de antígeno quimérico resistentes ao rituximabe e usos destes
US20220325346A1 (en) * 2019-07-09 2022-10-13 Selonterra, Inc. Use of snca-mediated genes for diagnosis and treatment of parkinson's disease
GB202010075D0 (en) * 2020-07-01 2020-08-12 Imp College Innovations Ltd Therapeutic nucleic acids, peptides and uses
CN117897167A (zh) * 2021-05-13 2024-04-16 福奇生物制品公司 腺病毒辅助质粒
CN114790463B (zh) * 2022-04-15 2023-10-13 中山大学 稳定转染CRISPR/dCas9系统的单克隆细胞株的构建方法及其应用
EP4342988A1 (en) 2022-09-20 2024-03-27 Eberhard Karls Universität Tübingen, Medizinische Fakultät Compositions and methods for modification of the expression of a snca gene
CN120230839A (zh) * 2025-04-30 2025-07-01 北京凯祥弘康生物科技有限公司 一种检测snca基因dna甲基化水平的引物探针组合物及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521555A (ja) * 2013-06-05 2016-07-25 デューク ユニバーシティ Rnaガイド遺伝子編集及び遺伝子調節
JP2016521995A (ja) * 2013-06-17 2016-07-28 ザ・ブロード・インスティテュート・インコーポレイテッド ウイルス成分を使用して障害および疾患をターゲティングするためのCRISPR−Cas系および組成物の送達、使用および治療上の適用
WO2016205749A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2016205711A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
JP2017501149A (ja) * 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド 粒子送達構成成分を用いた障害及び疾患の標的化のためのcrispr−cas系及び組成物の送達、使用及び治療適用
US20170035860A1 (en) * 2015-04-02 2017-02-09 Alexander C. Flynn Compositions and methods for treatment of neurogenerative diseases
WO2018035495A1 (en) * 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10676726B2 (en) * 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
EP3091087A1 (en) * 2015-05-08 2016-11-09 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts
WO2018154418A1 (en) * 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521555A (ja) * 2013-06-05 2016-07-25 デューク ユニバーシティ Rnaガイド遺伝子編集及び遺伝子調節
JP2016521995A (ja) * 2013-06-17 2016-07-28 ザ・ブロード・インスティテュート・インコーポレイテッド ウイルス成分を使用して障害および疾患をターゲティングするためのCRISPR−Cas系および組成物の送達、使用および治療上の適用
JP2017501149A (ja) * 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド 粒子送達構成成分を用いた障害及び疾患の標的化のためのcrispr−cas系及び組成物の送達、使用及び治療適用
US20170035860A1 (en) * 2015-04-02 2017-02-09 Alexander C. Flynn Compositions and methods for treatment of neurogenerative diseases
WO2016205749A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2016205711A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2018035495A1 (en) * 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHMAD JOWAED ET AL., THE JOURNAL OF NEUROSCIENCE, vol. 30, no. 18, JPN6023018137, 2010, pages 6355 - 6359, ISSN: 0005342000 *
LUMINE MATSUMOTO ET AL., PLOS ONE, vol. Vol. 5, Issue 11, e15522, JPN6023018135, 2010, pages 1 - 9, ISSN: 0005052413 *
SUBHRANGSHU GUHATHAKURTA ET AL., PROGRESS IN NEUROBIOLOGY, vol. 154, JPN6023018136, 2017, pages 21 - 36, ISSN: 0005342001 *

Also Published As

Publication number Publication date
US20210189361A1 (en) 2021-06-24
WO2019209869A3 (en) 2019-12-26
AU2019261361A1 (en) 2020-11-19
EP3784785A4 (en) 2022-02-16
EP3784785A2 (en) 2021-03-03
JP2024073420A (ja) 2024-05-29
CN112166194A (zh) 2021-01-01
WO2019209869A2 (en) 2019-10-31
CA3097755A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7854214B2 (ja) Rnaガイド遺伝子編集及び遺伝子調節
JP2024073420A (ja) Dnaメチル化の標的化された編集によるsnca発現の下方調節
US20220305141A1 (en) Skeletal myoblast progenitor cell lineage specification by crispr/cas9-based transcriptional activators
US20220307015A1 (en) Compositions and methods for identifying regulators of cell type fate specification
WO2017015101A1 (en) Methods for maximizing the efficiency of targeted gene correction
US20260139248A1 (en) Direct reprogramming of human astrocytes to neurons with crispr-based transcriptional activation
US20250313819A1 (en) Therapeutic crispr/cas9 gene editing approaches to the c9orf72 repeat expansion mutation in ipscs
HK40045174A (en) Downregulation of snca expression by targeted editing of dna-methylation
WO2024238494A2 (en) Therapeutic crispr/cas9 gene editing approaches to the c9orf72 repeat expansion mutation in ipscs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240326

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240614